Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GALECTIN THERAPEUTICS INCGALT · Entity 5577 | Chief Medical Officer | July 14, 2026 | July 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GALECTIN THERAPEUTICS INC
Report date July 14, 2026 · Filed July 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-07-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-14 · Exercise / conversion · Acquired 16,250 · Balance 16,250 F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 Row 2 · 2026-07-14 · Sale · Disposed 16,250 · Balance 0 F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 F2: The shares were sold in multiple transactions at prices ranging from $5.00 to $5.32. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.04 · Expires 2036-01-16 | Direct | 48,750 |
Reported balance
After 2026-07-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-14 · Exercise / conversion · Disposed 16,250 · Balance 48,750 F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 F3: The options vested at a rate of twenty five percent or 16,250 options on each of June 30, 2026; December 31, 2026; June 30, 2027; and December 31, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026
F2: The shares were sold in multiple transactions at prices ranging from $5.00 to $5.32. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3: The options vested at a rate of twenty five percent or 16,250 options on each of June 30, 2026; December 31, 2026; June 30, 2027; and December 31, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2024 Filed Aug 5, 2024 12:41 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantRestricted Stock Unit · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001133416-24-000052 · form4.xml · derivative · entry 2 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F4 · derivative.exercise_price: The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis. F3 · derivative.exercise_date: Restricted Stock Units vest 100% upon public announcement of Interim Analysis data from NAVIGATE clinical trial if such announcement is made on or before December 31, 2024 or they will expire unvested. F3 · derivative.expiration_date: Restricted Stock Units vest 100% upon public announcement of Interim Analysis data from NAVIGATE clinical trial if such announcement is made on or before December 31, 2024 or they will expire unvested. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 12:41 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001133416-24-000052 · form4.xml · derivative · entry 1 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-08-01 F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest as follows: 25% on each of October 31, 2024; January 31, 2025; April 30, 2025; and July 31, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.